{"id":827089,"date":"2025-03-18T13:15:03","date_gmt":"2025-03-18T17:15:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\/"},"modified":"2025-03-18T13:15:03","modified_gmt":"2025-03-18T17:15:03","slug":"neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\/","title":{"rendered":"NeuroOne\u00ae CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today\u2019s Marketplace &#8211; Update"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong>EDEN PRAIRIE, Minn., March  18, 2025  (GLOBE NEWSWIRE) &#8212; <\/strong>NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (&#8220;NeuroOne&#8221; or the &#8220;Company&#8221;), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that CEO Dave Rosa was featured on\u00a0<em>Today\u2019s Marketplace (TMP)<\/em> alongside Dr. Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The discussion explored the latest advancements in epilepsy treatment and NeuroOne\u2019s breakthrough OneRF<sup>\u00ae<\/sup> Ablation System.<\/p>\n<p align=\"justify\">The full interview can be <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Kt5grsTpR3vlZwFLfpqkyotFSPX63UAunoTs9ZROnypuX8MimjPXvet6C--RvjINPtzGX_K6ORElC9DrS5wUTmCHe6x0KGO51rzRpaZeK-SHStQY9NsX3R1BzRm7tdQYQkRt7UZMGKwKzF8hdY0tw-LQoIC76MCYc4EAP1q4PCMxsGFt1QToz3lkg6Kng81qcdD_srMxCP6xi1qsZpgbxOiRpZeXABlToavyZbhEwjt592HNeH6j93IdBsGkmNcyqnwX5AJ9ZmWTMP4Iw8OH6SRJh1CsMRX17bljtQQPwlYtatbIg925NC_iqK1w5dImkANtpiMhTE8tPIfb5YBdPABcgWod6j1vXwae15c5QqlGymPOyq6uElRbQBn90F-hQKlq8bKmj4QFqitjHWM58DiJ6jP4La7_TleiYINWrSPA5ReE9L5QOGUQ0RgmoWebCyXzxICZKs5ViwHSvKSgGy_isJ70Xk2AjGXqw8snsGA=\" rel=\"nofollow\" target=\"_blank\">viewed online here<\/a>.<\/p>\n<p align=\"justify\">Over 50 million people worldwide are affected by epilepsy, with nearly one-third of patients experiencing seizures that do not respond to medication. For these individuals, alternative treatment options, including Radiofrequency (RF) ablation therapy, offer a promising solution.<\/p>\n<p align=\"justify\">NeuroOne\u2019s OneRF<sup>\u00ae<\/sup> ablation system, is the first and only FDA 510(k)-cleared device capable of both recording brain activity and performing an RF ablation using the same device. The system has three main components: an electrode that stimulates, records and monitors brain activity with the capability to also perform an ablation, a temperature probe, and a radio frequency heat generator system.<\/p>\n<p align=\"justify\">&#8220;It was my pleasure to take part in this engaging conversation with Elizabeth Hart and Dr. Clark about the latest treatment options for epilepsy. The OneRF<sup>\u00ae<\/sup> system represents a significant advancement, offering a more efficient and precise approach for patients who still experience seizure activity after using traditional medication options,&#8221; said Dave Rosa, CEO of NeuroOne. &#8220;By combining real-time monitoring with targeted ablation in a single procedure, we are not only improving patient outcomes but also reducing the need for multiple invasive surgeries.&#8221;<\/p>\n<p align=\"justify\">To learn more about NeuroOne and its groundbreaking work in epilepsy treatment, as well as the potential for our OneRF<sup>\u00ae<\/sup> platform to be used in pain management, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_Ix-W7G1ObGuL1H-ItYkPlqopdJ5TF6dwMByPQlPIu_lpjCBU09h0sQSR7e4BXgnC-NjMIhp975MI0IYpyoZwCUG8JupVQNfntzcYD5uNmfw9s02Xb1O6KDLf_kWWqtZJ-PxbBsFEnVl8Jb4NfMHa2V9qaDYY7jXT4M_7eRcjcha1WrQLC8U8Ha-xsex2zt5zX_c3aIDy8OMkvOaN-h9HQnTrDh80KQyzpb7C8Mi1oxywH58uUApBw9GIlg2xegq1hAmBq4gvMRS_6h0bqlFsevodi4b_3FTKyuOFClKSAkkwLkHt8QaZw_jUb17coVllaIOACO4JhBWH_yFxGAw8m9etrq1RdmBkO5CtVDKqa2RXfGD0ms_cGDFMD4BfWSSZR0PMnw76cppIst2BW8bOZ6apC7gEpV3-Reh0DdDsKI=\" rel=\"nofollow\" target=\"_blank\">nmtc1.com<\/a><u>.<\/u><\/p>\n<p align=\"justify\">\n        <strong>About NeuroOne<\/strong>\n      <\/p>\n<p align=\"justify\">NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson\u2019s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_Ix-W7G1ObGuL1H-ItYkPn1VsQlY8Dazh_agLL37HU6dszHtgVjDEGJZJKheBL_zBFlxH6jIeEhuEJXkI39xicfYWXK3byXsT4oOWzR2DTIK_7qKck6_g_jK_-iIfnCp_ZwAI5dqZbs_ycUgmdeFyy19K03Rs4wgLpgemiEeEDhzet79LpjVXZpeQ4Su6WikJtbMXusCcSRXbWY4toGbZp-YHBEsfJhaPT9jcKmAOr6nb3c-cOItjAxZOUPgvc6F23nPGRL_3bXjg7CPq8-ridU2dMRsfVV8Hga0KZIvEEkaznRTwil0ydx5KyxjYPnkwO-jD3cu_vLg_yuZ6UDgqcmJvqjIMDuNVh5yDEUGzwwl6RYypKo4yZv3LCmQiKLiXGlBSw1P736TueVD_Y6aLAY3vnCmQyPiU_6-VqC7N54=\" rel=\"nofollow\" target=\"_blank\">nmtc1.com<\/a><u>.<\/u><\/p>\n<p align=\"justify\">\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward\u2013looking statement that reflects NeuroOne\u2019s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward\u2013looking statements by the words or phrases \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cforecasts,\u201d \u201cobjective,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ctarget,\u201d \u201cseek,\u201d \u201ccontemplate,\u201d \u201ccontinue, \u201cfocused on,\u201d \u201ccommitted to\u201d and \u201congoing,\u201d or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward\u2013looking statements may include statements regarding the potential for our OneRF\u00ae platform to be used in pain management our business strategy, market size, potential growth opportunities, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations for the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements, risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our technology\u037e whether due to supply chain disruptions, labor shortages or otherwise\u037e risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials\u037e risks related to uncertainties associated with the Company\u2019s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology\u037e uncertainties inherent in the development process of our technology\u037e risks related to changes in regulatory requirements or decisions of regulatory authorities\u037e that we may not have accurately estimated the size and growth potential of the markets for our technology\u037e risks relate to clinical trial patient enrollment and the results of clinical trials\u037e that we may be unable to protect our intellectual property rights\u037e and other risks, uncertainties and assumptions, including those described under the heading \u201cRisk Factors\u201d in our filings with the Securities and Exchange Commission. These forward\u2013looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward\u2013looking statements for any reason, even if new information becomes available in the future.<\/p>\n<p align=\"justify\">Caution: Federal law restricts this device to sale by or on the order of a physician.<\/p>\n<p>\n        <strong>IR Contact<\/strong>\n      <\/p>\n<p>Chris Donovan<br \/>MZ Group \u2013 MZ North America<br \/>(914) 352-5853<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YCP0UMThdTi2vnmWhT8U2T0rz6hYk8Hk9kY7UCofYLhhuy4hm8PGq639KkaSUJ4-1m_B2TUSiBXUj7yu7dteEAHtUks9Gm8RgZbILM-O516ZMJJ56Kk1LMFL3n7HVqrsoJcaXNJ2SaeWp0kdBfqXQNDQHCXYLAyvSG5XhDvPeZAqB1YlBpuXo4Dk5sG2-q7I_IUVHvfkw3gM6dKxKbSfU1EwPiWxLLrUbUwLplXLbdtXqHw5WJNzf5dG_SHG90j2q1OjrKKtNb0kBUnsTt6zrg==\" rel=\"nofollow\" target=\"_blank\">NMTC@mzgroup.us<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjUzMiM2ODEyMTkzIzUwMDExNDgzNA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YWQ1YzI3MDktOGExMi00MjBhLTljYjAtY2M0Njc3ZTE2N2I5LTUwMDExNDgzNC0yMDI1LTAzLTE4LWVu\/tiny\/NeuroOne-Medical-Technologies-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>EDEN PRAIRIE, Minn., March 18, 2025 (GLOBE NEWSWIRE) &#8212; NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (&#8220;NeuroOne&#8221; or the &#8220;Company&#8221;), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that CEO Dave Rosa was featured on\u00a0Today\u2019s Marketplace (TMP) alongside Dr. Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The discussion explored the latest advancements in epilepsy treatment and NeuroOne\u2019s breakthrough OneRF\u00ae Ablation System. The full interview can be viewed online here. Over 50 million people worldwide are affected by epilepsy, with nearly one-third of patients experiencing seizures that do not respond to medication. For these individuals, alternative treatment options, including Radiofrequency (RF) ablation therapy, offer &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NeuroOne\u00ae CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today\u2019s Marketplace &#8211; Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-827089","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NeuroOne\u00ae CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today\u2019s Marketplace - Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeuroOne\u00ae CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today\u2019s Marketplace - Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"EDEN PRAIRIE, Minn., March 18, 2025 (GLOBE NEWSWIRE) &#8212; NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (&#8220;NeuroOne&#8221; or the &#8220;Company&#8221;), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that CEO Dave Rosa was featured on\u00a0Today\u2019s Marketplace (TMP) alongside Dr. Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The discussion explored the latest advancements in epilepsy treatment and NeuroOne\u2019s breakthrough OneRF\u00ae Ablation System. The full interview can be viewed online here. Over 50 million people worldwide are affected by epilepsy, with nearly one-third of patients experiencing seizures that do not respond to medication. For these individuals, alternative treatment options, including Radiofrequency (RF) ablation therapy, offer &hellip; Continue reading &quot;NeuroOne\u00ae CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today\u2019s Marketplace &#8211; Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-18T17:15:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjUzMiM2ODEyMTkzIzUwMDExNDgzNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeuroOne\u00ae CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today\u2019s Marketplace &#8211; Update\",\"datePublished\":\"2025-03-18T17:15:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\\\/\"},\"wordCount\":912,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjUzMiM2ODEyMTkzIzUwMDExNDgzNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\\\/\",\"name\":\"NeuroOne\u00ae CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today\u2019s Marketplace - Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjUzMiM2ODEyMTkzIzUwMDExNDgzNA==\",\"datePublished\":\"2025-03-18T17:15:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjUzMiM2ODEyMTkzIzUwMDExNDgzNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjUzMiM2ODEyMTkzIzUwMDExNDgzNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeuroOne\u00ae CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today\u2019s Marketplace &#8211; Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeuroOne\u00ae CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today\u2019s Marketplace - Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\/","og_locale":"en_US","og_type":"article","og_title":"NeuroOne\u00ae CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today\u2019s Marketplace - Update - Market Newsdesk","og_description":"EDEN PRAIRIE, Minn., March 18, 2025 (GLOBE NEWSWIRE) &#8212; NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (&#8220;NeuroOne&#8221; or the &#8220;Company&#8221;), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that CEO Dave Rosa was featured on\u00a0Today\u2019s Marketplace (TMP) alongside Dr. Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The discussion explored the latest advancements in epilepsy treatment and NeuroOne\u2019s breakthrough OneRF\u00ae Ablation System. The full interview can be viewed online here. Over 50 million people worldwide are affected by epilepsy, with nearly one-third of patients experiencing seizures that do not respond to medication. For these individuals, alternative treatment options, including Radiofrequency (RF) ablation therapy, offer &hellip; Continue reading \"NeuroOne\u00ae CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today\u2019s Marketplace &#8211; Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-18T17:15:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjUzMiM2ODEyMTkzIzUwMDExNDgzNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeuroOne\u00ae CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today\u2019s Marketplace &#8211; Update","datePublished":"2025-03-18T17:15:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\/"},"wordCount":912,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjUzMiM2ODEyMTkzIzUwMDExNDgzNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\/","name":"NeuroOne\u00ae CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today\u2019s Marketplace - Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjUzMiM2ODEyMTkzIzUwMDExNDgzNA==","datePublished":"2025-03-18T17:15:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjUzMiM2ODEyMTkzIzUwMDExNDgzNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjUzMiM2ODEyMTkzIzUwMDExNDgzNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-ceo-dave-rosa-discusses-epilepsy-treatment-innovations-on-todays-marketplace-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeuroOne\u00ae CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today\u2019s Marketplace &#8211; Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827089","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=827089"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827089\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=827089"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=827089"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=827089"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}